As of 2026-01-05, the Intrinsic Value of Helix Biopharma Corp (HBP.TO) is -0.38 CAD. This HBP.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.40 CAD, the upside of Helix Biopharma Corp is -115.77%.
Based on its market price of 2.40 CAD and our intrinsic valuation, Helix Biopharma Corp (HBP.TO) is overvalued by 115.77%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.38 - -0.38 | -0.38 | -115.77% |
| P/E | (0.06) - (0.07) | (0.07) | -102.9% |
| DDM - Stable | (0.79) - (5.93) | (3.36) | -240.1% |
| DDM - Multi | (0.79) - (4.71) | (1.37) | -157.0% |
| Market Cap (mil) | 183.31 |
| Beta | 3.31 |
| Outstanding shares (mil) | 76.38 |
| Enterprise Value (mil) | 183.17 |
| Market risk premium | 5.10% |
| Cost of Equity | 7.31% |
| Cost of Debt | 5.00% |
| WACC | 7.30% |